GlassScriptPhysician profile
Neeraj Singh
NPI 1093919920
$132,811.91
in general payments reported to CMS, 2019-2025
32 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $24K · 2021: $12K · 2022: $18K · 2023: $9,182 · 2024: $21K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Consulting Fee: $4,075 · Food and Beverage: $3,931 · Travel and Lodging: $2,970 · Education: $89.83 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,315.00 |
| Consulting Fee | $4,075.00 |
| Food and Beverage | $3,930.84 |
| Travel and Lodging | $2,970.14 |
| Education | $89.83 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $66,141.26 | 2020-2025 | Acthar, Terlivaz |
| Veloxis Pharmaceuticals, INC. | $38,905.88 | 2019-2025 | Envarsus |
| Mallinckrodt Enterprises LLC | $14,574.99 | 2019 | |
| Vifor Pharma, INC. | $5,028.95 | 2020-2023 | Veltassa |
| Vertex Pharmaceuticals Incorporated | $3,575.00 | 2025 | |
| Travere Therapeutics, INC. | $1,214.61 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $640.56 | 2019-2025 | Lokelma |
| Calliditas Therapeutics US INC. | $463.88 | 2023-2024 | Tarpeyo |
| La Jolla Pharmaceutical Company | $322.63 | 2021-2023 | Xacduro |
| Melinta Therapeutics, LLC | $302.38 | 2023-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Eurofins Viracor, LLC | $243.09 | 2020 | |
| Sanofi-Aventis U.S. LLC | $150.00 | 2024 | |
| Insmed, INC. | $127.58 | 2020 | |
| Aurinia Pharma U.S., INC. | $125.00 | 2022 | |
| Paratek Pharmaceuticals, INC. | $124.47 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $119.70 | 2024 | Soliris |
| Merck Sharp & Dohme LLC | $108.72 | 2023-2025 | Prevymis, Winrevair |
| Horizon Therapeutics Plc | $108.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $101.41 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $92.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.83 | 2023-2025 | Livtencity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.08 | 2020 | |
| Amgen INC. | $45.09 | 2019 | |
| Dova Pharmaceuticals | $30.54 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $23.60 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.05 | 2021 | |
| Glaxosmithkline, LLC. | $17.61 | 2022 | |
| Apellis Pharmaceuticals, INC. | $16.89 | 2025 | Empaveli |
| Conmed Corporation | $16.85 | 2019 | |
| Medtronic, INC. | $15.39 | 2025 | Signia |
| Opko Pharmaceuticals, LLC | $14.84 | 2023 | Rayaldee |
| Intercept Pharmaceuticals, INC. | $14.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeraj Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.